XRAY DENTSPLY SIRONA Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dentsply Sirona, Inc.

Levi & Korsinsky announces it has commenced an investigation of Dentsply Sirona, Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) concerning possible violations of federal securities laws.

On August 9, 2017, Dentsply revealed second quarter 2017 earnings that were below its expectations, and announced an SEC investigation “concerning the Company's accounting and disclosures, including its accounting and disclosures relating to transactions with a significant distributor of the Company.” Following this news, Dentsply stock fell 8.44% to close at $56.23 per share on August 9, 2017. To obtain additional information, go to:

http://www.zlkdocs.com/XRAY-Info-Request-Form-6032

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
10/08/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

Dentsply Sirona Inc: 2 directors

Two Directors at Dentsply Sirona Inc bought 20,000 shares at between 12.445USD and 12.480USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

 PRESS RELEASE

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleare...

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and ort...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Dentsply Sirona Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 March 2026 in which we reassessed the appropriateness of the ratings in the context ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch